Evotec SE (EVO)
USD 4.33
(-9.41%)
USD 4.33
(-9.41%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.29 Billion EUR | 1.85% |
| 2022 | 2.25 Billion EUR | 0.99% |
| 2021 | 2.23 Billion EUR | 52.79% |
| 2020 | 1.46 Billion EUR | 23.88% |
| 2019 | 1.18 Billion EUR | 52.99% |
| 2018 | 771.88 Million EUR | 15.68% |
| 2017 | 667.26 Million EUR | 89.91% |
| 2016 | 351.36 Million EUR | 21.77% |
| 2015 | 288.53 Million EUR | 28.47% |
| 2014 | 224.6 Million EUR | -1.22% |
| 2013 | 227.38 Million EUR | 0.87% |
| 2012 | 225.42 Million EUR | 3.31% |
| 2011 | 218.21 Million EUR | 13.74% |
| 2010 | 191.85 Million EUR | 30.87% |
| 2009 | 146.59 Million EUR | -19.85% |
| 2008 | 182.9 Million EUR | -12.02% |
| 2007 | 207.87 Million EUR | 1.14% |
| 2006 | 205.52 Million EUR | 10.43% |
| 2005 | 186.11 Million EUR | 162.46% |
| 2004 | 70.9 Million EUR | 69.94% |
| 2003 | 41.72 Million EUR | 123.1% |
| 2002 | 18.7 Million EUR | -48.34% |
| 2001 | 36.2 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.99 Billion EUR | -9.5% |
| 2024 Q1 | 2.2 Billion EUR | -3.93% |
| 2023 FY | 2.29 Billion EUR | 1.85% |
| 2023 Q2 | 2.3 Billion EUR | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q3 | 2.25 Billion EUR | -2.03% |
| 2023 Q4 | 2.29 Billion EUR | 1.98% |
| 2022 Q4 | 2.25 Billion USD | -0.24% |
| 2022 Q3 | 2.26 Billion EUR | -1.35% |
| 2022 Q2 | 2.29 Billion EUR | 4.97% |
| 2022 Q1 | 2.18 Billion EUR | -2.24% |
| 2022 FY | 2.25 Billion EUR | 0.99% |
| 2021 Q4 | 2.23 Billion EUR | 26.43% |
| 2021 FY | 2.23 Billion EUR | 52.79% |
| 2021 Q2 | 1.62 Billion EUR | 2.56% |
| 2021 Q1 | 1.58 Billion EUR | 8.05% |
| 2021 Q3 | 1.76 Billion EUR | 9.05% |
| 2020 Q2 | 1.19 Billion EUR | 0.6% |
| 2020 Q1 | 1.18 Billion EUR | 0.22% |
| 2020 Q4 | 1.46 Billion EUR | 25.07% |
| 2020 Q3 | 1.16 Billion EUR | -1.76% |
| 2020 FY | 1.46 Billion EUR | 23.88% |
| 2019 FY | 1.18 Billion EUR | 52.99% |
| 2019 Q4 | 1.18 Billion EUR | 8.95% |
| 2019 Q3 | 1.08 Billion EUR | 1.53% |
| 2019 Q1 | 880.82 Million EUR | 14.11% |
| 2019 Q2 | 1.06 Billion EUR | 21.21% |
| 2018 Q4 | 771.88 Million EUR | 0.2% |
| 2018 Q2 | 693.76 Million EUR | 4.28% |
| 2018 FY | 771.88 Million EUR | 15.68% |
| 2018 Q1 | 665.3 Million EUR | -0.29% |
| 2018 Q3 | 770.34 Million EUR | 11.04% |
| 2017 Q2 | 421.48 Million EUR | 0.65% |
| 2017 Q1 | 418.75 Million EUR | 19.18% |
| 2017 FY | 667.26 Million EUR | 89.91% |
| 2017 Q4 | 667.26 Million EUR | 3.61% |
| 2017 Q3 | 644 Million EUR | 52.8% |
| 2016 Q1 | 274.96 Million EUR | -4.7% |
| 2016 FY | 351.36 Million EUR | 21.77% |
| 2016 Q4 | 351.36 Million EUR | 27.23% |
| 2016 Q3 | 276.17 Million EUR | 1.59% |
| 2016 Q2 | 271.86 Million EUR | -1.13% |
| 2015 Q1 | 227.99 Million EUR | 1.51% |
| 2015 FY | 288.53 Million EUR | 28.47% |
| 2015 Q3 | 284.48 Million EUR | -2.13% |
| 2015 Q4 | 288.53 Million EUR | 1.42% |
| 2015 Q2 | 290.67 Million EUR | 27.49% |
| 2014 Q1 | 219.62 Million EUR | -3.41% |
| 2014 FY | 224.6 Million EUR | -1.22% |
| 2014 Q4 | 224.6 Million EUR | 5.12% |
| 2014 Q3 | 213.65 Million EUR | -3.16% |
| 2014 Q2 | 220.62 Million EUR | 0.45% |
| 2013 Q1 | 221.96 Million EUR | -1.54% |
| 2013 Q4 | 227.38 Million EUR | -7.52% |
| 2013 FY | 227.38 Million EUR | 0.87% |
| 2013 Q3 | 245.87 Million EUR | 13.53% |
| 2013 Q2 | 216.57 Million EUR | -2.42% |
| 2012 Q4 | 225.42 Million EUR | -0.94% |
| 2012 Q1 | 214.24 Million EUR | -1.82% |
| 2012 Q2 | 215.75 Million EUR | 0.7% |
| 2012 Q3 | 227.57 Million EUR | 5.48% |
| 2012 FY | 225.42 Million EUR | 3.31% |
| 2011 Q3 | 212.91 Million EUR | 6.11% |
| 2011 Q4 | 218.21 Million EUR | 2.49% |
| 2011 Q1 | 186.31 Million EUR | -2.89% |
| 2011 Q2 | 200.65 Million EUR | 7.7% |
| 2011 FY | 218.21 Million EUR | 13.74% |
| 2010 Q4 | 191.85 Million EUR | 7.66% |
| 2010 FY | 191.85 Million EUR | 30.87% |
| 2010 Q3 | 178.2 Million EUR | 17.71% |
| 2010 Q2 | 151.38 Million EUR | 4.74% |
| 2010 Q1 | 144.53 Million EUR | -1.41% |
| 2009 Q4 | 146.59 Million EUR | -5.22% |
| 2009 Q1 | 175.34 Million EUR | -4.13% |
| 2009 Q2 | 161.25 Million EUR | -8.04% |
| 2009 Q3 | 154.67 Million EUR | -4.08% |
| 2009 FY | 146.59 Million EUR | -19.85% |
| 2008 Q2 | 228.53 Million EUR | 23.8% |
| 2008 Q4 | 182.9 Million EUR | -18.56% |
| 2008 Q3 | 224.59 Million EUR | -1.72% |
| 2008 FY | 182.9 Million EUR | -12.02% |
| 2008 Q1 | 184.6 Million USD | -11.34% |
| 2007 FY | 207.87 Million EUR | 1.14% |
| 2007 Q3 | 206.04 Million EUR | 0.0% |
| 2007 Q4 | 208.2 Million EUR | 1.05% |
| 2006 Q3 | 89.68 Million EUR | -2.63% |
| 2006 Q2 | 92.11 Million EUR | -8.3% |
| 2006 Q4 | 243.12 Million EUR | 171.07% |
| 2006 FY | 205.52 Million EUR | 10.43% |
| 2006 Q1 | 100.45 Million EUR | -6.03% |
| 2005 FY | 186.11 Million EUR | 162.46% |
| 2005 Q2 | 64.28 Million EUR | 0.0% |
| 2005 Q1 | - EUR | -100.0% |
| 2005 Q4 | 106.89 Million EUR | 0.0% |
| 2004 Q1 | - EUR | -100.0% |
| 2004 FY | 70.9 Million EUR | 69.94% |
| 2004 Q4 | 70.9 Million EUR | 0.0% |
| 2004 Q2 | - EUR | 0.0% |
| 2003 FY | 41.72 Million EUR | 123.1% |
| 2003 Q4 | 41.72 Million EUR | 0.0% |
| 2002 FY | 18.7 Million EUR | -48.34% |
| 2001 FY | 36.2 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Cumberland Pharmaceuticals Inc. | 81.77 Million USD | -2711.401% |
| Harrow Health, Inc. | 311.75 Million USD | -637.455% |
| Dynavax Technologies Corporation | 997.09 Million USD | -130.575% |
| Biofrontera Inc. | 27.93 Million USD | -8130.893% |
| DURECT Corporation | 45.18 Million USD | -4987.639% |
| Cronos Group Inc. | 1.13 Billion USD | -102.693% |
| Ironwood Pharmaceuticals, Inc. | 471.07 Million USD | -388.046% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -4009.194% |
| RedHill Biopharma Ltd. | 23.04 Million USD | -9875.439% |
| Guardion Health Sciences, Inc. | 11.91 Million USD | -19190.308% |
| Radius Health, Inc. | 1.71 Billion USD | -33.981% |
| Universe Pharmaceuticals INC | 53.28 Million USD | -4214.47% |
| ProPhase Labs, Inc. | 91.92 Million USD | -2400.955% |
| Phibro Animal Health Corporation | 982.18 Million USD | -134.076% |
| China SXT Pharmaceuticals, Inc. | 23.12 Million USD | -9840.967% |
| Procaps Group S.A. | 460.18 Million USD | -399.591% |
| Alvotech | 950.09 Million USD | -141.983% |
| TherapeuticsMD, Inc. | 43.3 Million USD | -5208.488% |
| Rockwell Medical, Inc. | 52.17 Million USD | -4306.595% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -8306.978% |
| Alpha Teknova, Inc. | 128.58 Million USD | -1687.936% |
| Intra-Cellular Therapies, Inc. | 728.29 Million USD | -215.676% |
| SCYNEXIS, Inc. | 128.41 Million USD | -1690.372% |
| Aytu BioPharma, Inc. | 118.09 Million USD | -1846.783% |
| Theratechnologies Inc. | 77.76 Million USD | -2856.259% |
| ANI Pharmaceuticals, Inc. | 904.42 Million USD | -154.201% |
| Sonoma Pharmaceuticals, Inc. | 14.89 Million USD | -15337.138% |
| Safety Shot Inc | 12.7 Million USD | -17989.704% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -63.172% |
| SIGA Technologies, Inc. | 254.83 Million USD | -802.169% |
| Tilray Brands, Inc. | 4.33 Billion USD | 46.969% |
| Lifecore Biomedical, Inc. | 273.7 Million USD | -739.984% |
| Viatris Inc. | 47.68 Billion USD | 95.179% |
| PetIQ, Inc. | 868.22 Million USD | -164.799% |
| OptiNose, Inc. | 107.72 Million USD | -2034.108% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 29.29% |
| Sunshine Biopharma, Inc. | 27.34 Million USD | -8306.978% |
| Organogenesis Holdings Inc. | 460.02 Million USD | -399.767% |
| Alimera Sciences, Inc. | 153.52 Million USD | -1397.52% |
| Collegium Pharmaceutical, Inc. | 1.14 Billion USD | -101.088% |
| Silver Spike Investment Corp. | 88.57 Million USD | -2495.563% |
| Assertio Holdings, Inc. | 286.41 Million USD | -702.689% |
| Shuttle Pharmaceuticals Holdings, Inc. | 5.95 Million USD | -38528.276% |
| Cosmos Health Inc. | 66.29 Million USD | -3367.883% |
| Journey Medical Corporation | 76.84 Million USD | -2891.65% |
| Petros Pharmaceuticals, Inc. | 33.79 Million USD | -6702.778% |
| Clever Leaves Holdings Inc. | 31.24 Million USD | -7258.618% |
| Embecta Corp. | 1.21 Billion USD | -89.316% |
| Regencell Bioscience Holdings Limited | 8.43 Million USD | -27145.74% |
| Procaps Group, S.A. | 460.18 Million USD | -399.591% |
| PainReform Ltd. | 9.93 Million USD | -23052.598% |
| Incannex Healthcare Limited | 17.04 Million USD | -13386.555% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -17254.568% |
| Avadel Pharmaceuticals plc | 261.12 Million USD | -780.438% |
| Shineco, Inc. | 84.17 Million USD | -2631.136% |
| Talphera, Inc. | 20.39 Million USD | -11172.631% |
| Pacira BioSciences, Inc. | 1.57 Billion USD | -46.029% |
| Aquestive Therapeutics, Inc. | 57.41 Million USD | -3904.063% |
| Alvotech | 950.09 Million USD | -141.983% |
| Hempacco Co., Inc. | 18.04 Million USD | -12642.021% |
| Eagle Pharmaceuticals, Inc. | 406.16 Million USD | -466.046% |
| Lantheus Holdings, Inc. | 1.65 Billion USD | -39.24% |
| Bright Green Corporation | 17.4 Million USD | -13110.635% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -1017.151% |
| Kamada Ltd. | 351.96 Million USD | -553.196% |
| Indivior PLC | 1.95 Billion USD | -17.825% |
| Evoke Pharma, Inc. | 7.06 Million USD | -32425.119% |
| Flora Growth Corp. | 23.62 Million USD | -9631.029% |
| Cyclo Therapeutics, Inc. | 13.24 Million USD | -17254.568% |
| Evolus, Inc. | 188.99 Million USD | -1116.443% |
| HUTCHMED (China) Limited | 1.27 Billion USD | -79.645% |
| Amphastar Pharmaceuticals, Inc. | 1.51 Billion USD | -51.962% |
| Akanda Corp. | 8.83 Million USD | -25907.407% |